Pharmaceutical Information |
Drug Name |
Degarelix acetate |
Drug ID |
BADD_D00600 |
Description |
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. |
Indications and Usage |
Degaralix is used for the management of advanced prostate cancer. |
Marketing Status |
Prescription |
ATC Code |
L02BX02 |
DrugBank ID |
DB06699
|
KEGG ID |
D08635
|
MeSH ID |
C431566
|
PubChem ID |
16186010
|
TTD Drug ID |
D0Y7KH
|
NDC Product Code |
61662-0015; 70155-022 |
Synonyms |
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide | uglypeptide1 | Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2 | Firmagon | degarelix | degarelix acetate | Gonax | FE 200486 | FE200486 | FE-200486 |
|
Chemical Information |
Molecular Formula |
C84H107ClN18O18 |
CAS Registry Number |
934016-19-0 |
SMILES |
CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC
(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=
C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C.CC(=O)O |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
|